WASHINGTON — Researchers at Georgetown University’s Lombardi Comprehensive Cancer Center studied the microbiome of people with colorectal cancer and found the make-up of the bacteria, fungi and viruses in a person’s tumor varied significantly depending on whether they were diagnosed with early-onset disease (age 45 or younger) or late-onset disease (age 65 or older). These results may help answer the riddle of why more young people are developing colorectal cancer, particularly those who have no known identifiable risk factors for the disease.
The findings will be presented at the American Society of Clinical Oncology 2023 annual meeting in Chicago in June.
Colorectal cancer incidence rates have been declining for several decades in people over 55, in part because of the increased use of screening for the disease, particularly with colonoscopy which can find and remove polyps before they become cancerous. But nearly double the number of young adults under 55 are being diagnosed with colorectal cancer compared to a decade ago, with an increase in the incidence rate going from 11% in 1995 to 20% in 2020.
“Younger people with colorectal cancer have more biologically aggressive cancers and whatever survival benefit they have by being younger is outweighed by the more aggressive tumor biology. We also know, that for the most part, genetics doesn’t explain the recent rise in young-onset disease,” said Benjamin Adam Weinberg, MD, an associate professor of medicine at Georgetown Lombardi. “But we have trillions of bacteria residing in our body, including in our gut, some of which are implicated in the development of colorectal cancer, hence we think the microbiome may be an important factor in the development of the disease as it is involved in the interplay between a person’s genetics, environment, diet and immune system.”
Scientists have known for a while that certain microbes can disturb the lining of the colon and promote tissue inflammation. This can result in mutations to the DNA of cells in the colon and lead to cancer. Researchers also know that one type of bacteria, Fusobacterium nucleatum (F. nuc), can promote cancerous growth by suppressing immune responses in the colon.
To better understand the role of the microbiome and how its influence varies depending on a person’s age of onset of colorectal cancer, Weinberg and colleagues looked at the DNA and the microbiome of tumors from 36 patients with colorectal cancer who were diagnosed before age 45 as well as specimens from 27 people who were diagnosed after age 65.
Overall, the investigators detected 917 unique bacterial and fungal species in the tumors. One of the most common bacteria found was F. nuc, which appeared equally in about 30% of both early and late-onset tumors. Differences were seen in Cladosporium sp., which was found more commonly in early-onset disease, whereas Pseudomonas luteola, Ralstonia sp., and Moraxella osloensis were seen more commonly in late onset disease. In terms of composition, Clostridium perfringens, Escherichia coli, Leptotrichia hofstadii, Mycosphaerella sp., Neodevriesia modesta, Penicillium sp., and Leptosphaeria sp., each made up 11% of the microbiome in people with late-onset disease but these organisms were not found at all in people with early-onset disease.
Weinberg says with the current data, and with future efforts to collect more samples, they anticipate expanding their research efforts to continue exploring the relationship between the microbiome and other factors that contribute to colorectal cancer.
“Because we have tumor genetic data and diet questionnaire results from many of our patients, we hope to explore more relationships and other aspects of how the microbiome impacts colorectal cancer progression in the future,” said Weinberg. “We are also interested in the circulating microbiome, such as bacteria that could be picked up in a blood sample, and how this correlates with bacteria in the gut and in the tumor.”
In addition to Weinberg, authors include Hongkun Wang, Xue Geng, Robert K. Suter, Shrayus Sortur, Myra E. Green, Emily Bakhshi, Krysta Chaldekas, Brent T. Harris, Dionyssia Clagett and John Marshall at Georgetown. An additional author is Shadi Shokralla from Clear Labs, Menlo Park, CA.
This research was supported by the Colorectal Cancer Alliance and the Victoria Casey and Peter Teeley Foundation. Weinberg reports that he serves on advisory boards for Bayer, HalioDx, AstraZeneca/Daiichi Sankyo, and Merus, DoMore Diagnostics; serves on speakers bureaus for Lilly, Bayer, Taiho, Sirtex, HalioDx, AstraZeneca/Daiichi Sankyo, Merus, and Seagen; and has received travel funding from Caris and Merus.
About Georgetown University’s Lombardi Comprehensive Cancer Center
Georgetown’s Lombardi Comprehensive Cancer Center is designated by the National Cancer Institute (NCI) as a comprehensive cancer center. A part of Georgetown University Medical Center, Georgetown Lombardi is the only comprehensive cancer center in the Washington D.C. area. It serves as the research engine for MedStar Health, Georgetown University’s clinical partner. Georgetown Lombardi is also an NCI recognized consortium with John Theurer Cancer Center/Hackensack Meridian Health in Bergen County, New Jersey. The consortium reflects an integrated cancer research enterprise with scientists and physician-researchers from both locations. Georgetown Lombardi seeks to improve the diagnosis, treatment, and prevention of cancer through innovative basic, translational and clinical research, patient care, community education and outreach to service communities throughout the Washington region, while its consortium member John Theurer Cancer Center/Hackensack Meridian Health serves communities in northern New Jersey. Georgetown Lombardi is a member of the NCI Community Oncology Research Program (UG1CA239758). Georgetown Lombardi is supported in part by a National Cancer Institute Cancer Center Support Grant (P30CA051008). Connect with Georgetown Lombardi on Facebook (Facebook.com/GeorgetownLombardi) and Twitter (@LombardiCancer).
Method of Research
Subject of Research
Comprehensive study of the intratumoral microbiome in early- vs. late-onset colorectal cancer: Final analysis of COSMO CRC.
Article Publication Date
Weinberg reports that he serves on advisory boards for Bayer, HalioDx, AstraZeneca/Daiichi Sankyo, and Merus, DoMore Diagnostics; serves on speakers bureaus for Lilly, Bayer, Taiho, Sirtex, HalioDx, AstraZeneca/Daiichi Sankyo, Merus, and Seagen; and has received travel funding from Caris and Merus.